IVVD Stock — Invivyd Inc.: Cash, EV, Pipeline

What they do

Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody (“mAb”) therapies for the prevention and treatment of serious viral infectious diseases. We are devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.56

Market cap

$165.9M

Cash

$160.1M

Enterprise value

$5.8M

Balance sheet

Cash	$160.1M
Debt	$0.0M
Net cash	$160.1M
Enterprise value	$5.8M
Basic shares	294.8M shares
Fully diluted shares	362.9M shares
Fully diluted market cap	$203.2M
Cash per share	$0.54
Quarterly burn	$43.0M
Cash runway	3.7 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

294.8M

Pre-funded warrants

27.3M

Options

30.2M

RSUs

0.8M

Warrants

6.8M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

3.0M

FDSO

362.9M

Cap table as of 2026-06-30.

Price history

Loading IVVD daily closes…

Loading price history…

Recently reported

VYD2311 Phase 3 Positive · 2026-09-29

covid-19

Source release →

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

VYD2311

Phase 3 · Active Modality: monoclonal antibody

Target SARS-CoV-2

Partnerships Adimab: platform transfer agreement; WuXi Biologics: cell line license

Indications

COVID-19 prevention (Phase 3)

Catalysts

— Later Q3 2026
— Later Q3 2026

Status note REVOLUTION program includes three trials: DECLARATION (Phase 3 prevention, enrollment completed June 2026, supports potential BLA), LIBERTY (Phase 3 vs mRNA vaccine, fully dosed), and DRUMMER (pediatric, to be actioned only if DECLARATION succeeds). Fast Track designation for COVID-19 prevention.

PEMGARDA

Approved · Active Modality: monoclonal antibody (half-life extended)

Target SARS-CoV-2

Indications

COVID-19 pre-exposure prophylaxis (immunocompromised) (Stage not disclosed)

Catalysts

— June 29, 2027

Status note Authorized under EUA since March 22, 2024. Company in dialogue with FDA on next steps following EUA termination.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	VYD2311-SD
Lead indication	COVID-19
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07298434	Phase 3	Active, not recruiting	Sponsor	IVVD	—	COVID-19	Q3 2026
NCT07655180	Phase 3	Recruiting	Sponsor	IVVD	—	COVID-19	Q3 2026
NCT06523153	Phase 1	Active, not recruiting	Sponsor	IVVD	—	COVID-19	Q3 2026

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Invivyd, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
BVF Partners	28,165,000	+8,640,000	0.63%	2026-08-14
Perceptive Advisors	18,490,636	-2,368,667	0.25%	2026-08-14
ADAR1 Capital Management	3,807,427	-15,000	0.16%	2026-08-14
Ikarian Capital	2,656,570	no change	0.38%	2026-08-14
Boxer Capital	1,500,000	no change	0.10%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

IVVD — Invivyd Inc. ☆